OliX Pharmaceuticals, Inc

KOSDAQ:A226950 Stock Report

Market Cap: ₩310.3b

OliX Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Dong-Ki Lee

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership20.3%
Management average tenureno data
Board average tenure4.7yrs

Recent management updates

Recent updates

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump

Dec 07
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump

OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

Nov 15
OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Oct 09
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

Aug 22
Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22
We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Jun 25
It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13
OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Feb 17
Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

CEO

Dong-Ki Lee (52 yo)

no data

Tenure

Mr. Dong-Ki Lee Ph D., serves as Chief Executive Officer and Director at OliX Pharmaceuticals, Inc and was CSO until March 2021. Mr. Lee is a Professor of Global Research Laboratory(GRL) for RNAi Medicine...

Board Members

NamePositionTenureCompensationOwnership
Dong-Ki Lee
CEO & Directorno datano data20.33%
₩ 63.1b
Jong-Nam Seo
Directorno datano datano data
Aaron Hakim
Member of Scientific Advisory Board4.7yrsno datano data
Sun-Woo Hong
Directorno datano data0%
₩ 0
John Lis
Member of Scientific Advisory Boardno datano datano data
Sung-Hwa Hong
Directorno datano datano data
Demetrios Vavvas
Member of Science & Technology Advisory Board5.7yrsno datano data
Hyewon Chung
Member of Scientific Advisory Board5.9yrsno datano data
Yury Popov
Member of Scientific Advisory Board4.7yrsno datano data
Gordon Jiang
Member of Scientific Advisory Board4.7yrsno datano data
Tae-Gyeong Kim
Independent Outside Directorno datano data0%
₩ 0

4.7yrs

Average Tenure

53.5yo

Average Age

Experienced Board: A226950's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 00:25
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OliX Pharmaceuticals, Inc is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Taehee KimMirae Asset Securities Co., Ltd.
Wan KuNH Investment & Securities Co., Ltd.